Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rev Med Suisse ; 18(794): 1638-1643, 2022 Sep 07.
Artigo em Francês | MEDLINE | ID: mdl-36082382

RESUMO

In cases of severe bleeding on direct oral anticoagulant (DOAC) therapy, several hemostatic agents can be used with varying levels of evidence, including fresh frozen plasma and prothrombin complex concentrates. Recently, we have seen the emergence of specific antidotes to DOAC, such as idarucizumab and andexanet alfa, effective on anti-II and anti-Xa DOAC respectively. These new molecules have shown excellent biological efficacy, hence supporting their use in clinical practice, however they are not routinely used, mainly due to limited availability and high cost. Ciraparantag, an antagonist of DOAC and heparins currently in phase III trials, could become a key molecule in the future considering encouraging preliminary results.


En cas d'hémorragie sévère sous traitement par un anticoagulant oral direct (ACOD), plusieurs agents hémostatiques peuvent être utilisés avec un niveau d'évidence variable, notamment le plasma frais congelé et les concentrés de complexe prothrombinique. Récemment, nous avons vu l'émergence d'antidotes spécifiques aux ACOD, comme l'idarucizumab et l'andexanet alfa, neutralisant les ACOD anti-II et anti-Xa respectivement. Ces nouvelles molécules ont montré une bonne efficacité biologique justifiant leur utilisation en pratique mais leur administration n'est pas encore systématique, en raison notamment d'une disponibilité restreinte et d'un coût élevé. Le ciraparantag, antagoniste des ACOD et des héparines, en cours d'étude de phase III, pourrait devenir une molécule clé à l'avenir au vu de résultats préliminaires encourageants.


Assuntos
Anticoagulantes , Dabigatrana , Administração Oral , Anticoagulantes/farmacologia , Anticoagulantes/uso terapêutico , Antídotos/uso terapêutico , Dabigatrana/uso terapêutico , Hemorragia/tratamento farmacológico , Heparina de Baixo Peso Molecular/uso terapêutico , Humanos , Proteínas Recombinantes
2.
Artigo em Inglês | MEDLINE | ID: mdl-31751011

RESUMO

Since the first pediatric orthotopic heart transplant was performed by Dr Adrian Krantowicz in 1967, just days after the first ever human transplant by Dr Christiaan Barnard, the technique for orthotopic heart transplantation has evolved from biatrial anastomosis to separate caval anastomoses, leaving the right atrium intact. In this video tutorial, we present our technique for standard orthotopic heart transplantation in children.


Assuntos
Anastomose Cirúrgica/métodos , Transplante de Coração/métodos , Criança , Átrios do Coração/cirurgia , Humanos , Veias Cavas/cirurgia
3.
Cochabamba; s.n; 1997. 73 p. graf.
Tese em Espanhol | LIBOCS, LILACS, LIBOE | ID: biblio-1295811

RESUMO

Planteamiento del problema. Hipotesis. Metodología de la investigación. Métodos e instrumentos que emplearon para la recolección de datos. Marco teórico. Leishmaniasis cutánea. Leishmaniasis cutáneo-mucosa. Leishmaniasis visceral. Epidemiología de la leishmaniasis. Signos clínicos. Reservorio. El vector. El agente causal. Diagnóstico. Tratamiento. Medios de lucha y prevención. Definición de conceptos. Cobertura del programa. Presentación y análisis de los datos. Conclusiones y recomendaciones


Assuntos
Humanos , Bolívia , Leishmaniose , Prevalência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA